Exploring mechanisms of Huachansu in alleviating oxaliplatin-induced peripheral neuropathy via bioinformatic analysis and network pharmacology
CHEN Gongbo, LIU Lian, WANG Xinyue, WANG Xihui, XU Jingge, XU Qing, LIU Yayun, SHENG Deqiao, HUANG Yiling, YOU Chengcheng, GUO Yuhui, ZOU Yulin, YANG Yi
Objective To investigate the targets and mechanisms of Huachansu in alleviating oxaliplatin-induced peripheral neurotoxicity using bioinformatics and network pharmacology. Methods The targets of Huachansu were predicted via SwissTarget Prediction, PharmMapper, and SuperPred databases. Targets associated with oxaliplatin-induced peripheral neurotoxicity were retrieved from GeneCards, OMIM, and Harmonizome 3.0 databases. Combined with differential genes after oxaliplatin treatment from the GEO database, common targets were obtained through intersection analysis. The DAVID database was used for gene ontology (GO) function and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment. Core targets were screened via the PPI network and machine learning. Single-cell analysis was performed to explore the specific expression landscape of the core targets. AutoDock and Gromacs were employed for molecular docking and molecular dynamics simulation, with visualization assisted by PyMOL, QtGrace 2.6 and Python 3.7. Results A total of 37 active components of Huachansu were identified (e.g., telocinobufagin, hellebrigenol). Forty-five common targets were obtained. CCND1, PDGFRB, and other core targets were jointly determined by PPI network and machine learning. Molecular docking showed that telocinobufagin and other components exhibited binding energies of < -5 kcal/mol with Cyclin D1 (CCND1) and platelet-derived growth factor receptor beta (PDGFRB). Molecular dynamics simulation confirmed the stable binding between PDGFRB and telocinobufagin. Single-cell analysis suggested that Huachansu targets PDGFRB in stromal cells to reshape the neuro-supportive microenvironment. Conclusion Huachansu exerts neuroprotective effects at the acute OIPN stage by targeting PDGFRB+ neural stromal cells and activating the phosphatidylinositol-3-hydroxykinase (PI3K)-protein kinase B (Akt) signaling pathway, providing a theoretical basis for the early prevention of chemotherapy-induced neurotoxicity.
CHEN Gongbo, LIU Lian, WANG Xinyue, WANG Xihui, XU Jingge, XU Qing, LIU Yayun, SHENG Deqiao, HUANG Yiling, YOU Chengcheng, GUO Yuhui, ZOU Yulin, YANG Yi.
Exploring mechanisms of Huachansu in alleviating oxaliplatin-induced peripheral neuropathy via bioinformatic analysis and network pharmacology[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(15)
: 5999
-6014
.
DOI: 10.7501/j.issn.0253-2670.2026.15.018
Cheng F, Zhang R Q, Sun C, et al. Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: Mechanisms, pharmacokinetics and strategies [J]. Front Pharmacol, 2023, 14: 1231401. 陈珍雨, 刘璐, 姚舒宁, 等. 化疗诱发的周围神经病变毒性机制及中医药防治策略[J]. 中草药, 2026, 57(6): 2356-2367. Ali N T, Mohamed A A, Yousef B A. The incidence of oxaliplatin-induced peripheral neurotoxicity at Khartoum oncology hospital: A cross-sectional survey [J]. Asia Pac J Oncol Nurs, 2020, 7(3): 266-272. Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment [J]. Oncol Ther, 2021, 9(2): 385-450. Cavaletti G, Marmiroli P. Management of oxaliplatin-induced peripheral sensory neuropathy [J]. Cancers, 2020, 12(6): 1370. Sałat K. Chemotherapy-induced peripheral neuropathy: Part 2: Focus on the prevention of oxaliplatin-induced neurotoxicity [J]. Pharmacol Rep, 2020, 72(3): 508-527. 王宁军, 芦殿荣, 杨柳, 等. 华蟾素缓解癌性疼痛作用机制的研究进展[J]. 世界中西医结合杂志, 2016, 11(4): 590-592. 宋少晨, 张冠南, 李柳, 等. 基于癌毒病机理论探讨华蟾素治疗消化系统恶性肿瘤及其作用机制[J]. 中国中药杂志, 2025, 50(21): 5999-6007. 周秀丽, 刘宝生, 马文明, 等. 华蟾素制剂在肿瘤患者的临床使用分析[J]. 中国药物警戒, 2024, 21(7): 791-797. 巴茜远, 周诗旸, 罗欣欣, 等. 华蟾素抗癌性疼痛的药理作用及作用机制的研究进展[J]. 中国疼痛医学杂志, 2019, 25(9): 695-698. Nogales C, Mamdouh Z M, List M, et al. Network pharmacology: Curing causal mechanisms instead of treating symptoms [J]. Trends Pharmacol Sci, 2022, 43(2): 136-150. 牛明, 张斯琴, 张博, 等. 《网络药理学评价方法指南》解读[J]. 中草药, 2021, 52(14): 4119-4129. Besli N, Ercin N, Celik U, et al. How to expedite drug discovery: Integrating innovative approaches to accelerate modern drug development [J]. ACSi, 2025: 581-600. Inayatullah M, Dwivedi A K, Tiwari V K. Advances in single-cell omics: Transformative applications in basic and clinical research [J]. Curr Opin Cell Biol, 2025, 95: 102548. Yan D J, Ma Y, Chen X, et al. Molecular dynamics-driven drug discovery [J]. Phys Chem Chem Phys, 2025, 27(24): 12633-12651. Yang Z T, Wang Y F, Huang S C, et al. Identification of potential anti-tumor targets and mechanisms of Huachansu Injection using network pharmacology and cytological experiments in breast cancer [J]. PLoS One, 2024, 19(5): e0303650. Deng Y Q, Gao M, Lu D, et al. Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities [J]. Phytomedicine, 2024, 123: 155169. Huang J H, Chen F Y, Zhong Z F, et al. Interpreting the pharmacological mechanisms of Huachansu Capsules on hepatocellular carcinoma through combining network pharmacology and experimental evaluation [J]. Front Pharmacol, 2020, 11: 414. 吴欢, 唐卯星, 陶欣怡, 等. UPLC-ESI-QTOF/MS^E结合UNIFI快速分析华蟾素注射液化学成分[J]. 天然产物研究与开发, 2020, 32(3): 498-506. 王卫锋, 罗红锁, 李捷. 高效液相色谱法测定华蟾素片中华蟾素毒基和脂蟾毒配基含量[J]. 中国药业, 2010, 19(10): 36-37. 吴毅, 许妍, 赵雯, 等. HPLC法同时检查华蟾素片中蟾毒灵、华蟾酥毒基及酯蟾毒配基限量和测定蟾蜍噻咛的含量[J]. 中国药事, 2012, 26(1): 53-56. Velasco R, Alemany M, Villagrán M, et al. Predictive biomarkers of oxaliplatin-induced peripheral neurotoxicity [J]. J Pers Med, 2021, 11(7): 669. Yang Y, Zhao B, Gao X J, et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy: Clinical syndrome, molecular basis, and drug development [J]. J Exp Clin Cancer Res, 2021, 40(1): 331. Calls A, Torres-Espin A, Tormo M, et al. A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice [J]. Ann Clin Transl Neurol, 2022, 9(12): 1985-1998. Mahmoud O, Oladipo O, Mahmoud R H, et al. Itch: From the skin to the brain–peripheral and central neural sensitization in chronic itch [J]. Front Mol Neurosci, 2023, 16: 1272230. Song Q B, E S H, Zhang Z Y, et al. Neuroplasticity in the transition from acute to chronic pain [J]. Neurotherapeutics, 2024, 21(6): e00464. Jang Y, Kim M, Hwang S W. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception [J]. J Neuroinflammation, 2020, 17(1): 30. Chen Y Y, Liu S Y, Wu L L, et al. Epigenetic regulation of chemokine (CC-motif) ligand 2 in inflammatory diseases [J]. Cell Prolif, 2023, 56(7): e13428. Zhang Y, Shu X H, Zhang Y, et al. Astrocyte-derived MMP-9 is a key mediator of pseudorabies virus penetration of the blood-brain barrier and tight junction disruption [J]. Vet Res, 2025, 56(1): 72. McQuade R M, Stojanovska V, Bornstein J C, et al. PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection [J]. Pharmacol Res, 2018, 137: 104-113. Guo Y, Yu Y H. PI3K/Akt pathway and neuroinflammation in sepsis-associated encephalopathy [J]. Open Med, 2025, 20: 20251248. Duan Z D, Peng Y Q, Xu D Y, et al. Scutellarin alleviates neuronal apoptosis in ischemic stroke via activation of the PI3K/AKT signaling pathway [J]. Int J Mol Sci, 2025, 26(5): 2175. Chen T B, Yu L C, Cai Z J, et al. Identification and experimental validation of biomarkers associated with PI3K/AKT signaling pathway in spinal cord injury [J]. Mol Neurobiol, 2026, 63(1): 572. Liu T L, Li X L, Zhou X W, et al. PI3K/AKT signaling and neuroprotection in ischemic stroke: Molecular mechanisms and therapeutic perspectives [J]. Neural Regen Res, 2025, 20(10): 2758-2775. Sprenger-Svačina A, Svačina M K R, Otlu H G, et al. Endoneurial immune interplay in peripheral nerve repair: Insights and implications for future therapeutic interventions [J]. Front Neurosci, 2025, 19: 1602112. Hara M, Kadoya K, Endo T, et al. Peripheral nerve-derived fibroblasts promote neurite outgrowth in adult dorsal root ganglion neurons more effectively than skin-derived fibroblasts [J]. Exp Physiol, 2023, 108(4): 621-635. Reinhold A K, Hartmannsberger B, Burek M, et al. Stabilizing the neural barrier–A novel approach in pain therapy [J]. Pharmacol Ther, 2023, 249: 108484. Heming M, Börsch A L, Wolbert J, et al. Multi-omic identification of perineurial hyperplasia and lipid-associated nerve macrophages in human polyneuropathies [J]. Nat Commun, 2025, 16: 7872. Sharma K, Zhang Y P, Paudel K R, et al. The emerging role of pericyte-derived extracellular vesicles in vascular and neurological health [J]. Cells, 2022, 11(19): 3108. Shimizu F, Sano Y, Abe M A, et al. Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors [J]. J Cell Physiol, 2011, 226(1): 255-266. Gaceb A, Özen I, Padel T, et al. Pericytes secrete pro-regenerative molecules in response to platelet-derived growth factor-BB [J]. J Cereb Blood Flow Metab, 2018, 38(1): 45-57. Jindatip D, Nopparat W, Kobutree P, et al. Pericyte loss and detachment in experimental cisplatin-induced neuropathy [J]. Int J Morphol, 2019, 37(2): 509-514. Tothonglor A, Kobutree P, Roumwong A, et al. Cisplatin-induced alterations in the blood-nerve barrier: Effects of combination of vitamin B1, B6 and B12[J]. Folia Morphol, 2023, 82(1): 53-62. Patai R, Csik B, Nyul-Toth A, et al. Persisting blood–brain barrier disruption following cisplatin treatment in a mouse model of chemotherapy-associated cognitive impairment [J]. GeroScience, 2025, 47(3): 3835-3847. Shen J, Xu G H, Zhu R X, et al. PDGFR-β restores blood-brain barrier functions in a mouse model of focal cerebral ischemia [J]. J Cereb Blood Flow Metab, 2019, 39(8): 1501-1515. Sweeney M D, Ayyadurai S, Zlokovic B V. Pericytes of the neurovascular unit: Key functions and signaling pathways [J]. Nat Neurosci, 2016, 19(6): 771-783. Yang H X, Chen Y X, Dai C L, et al. Huachansu suppresses colorectal cancer via inhibiting PI3K/AKT and glycolysis signaling pathways: Systems biology and network pharmacology [J]. J Ethnopharmacol, 2025, 343: 119479. Tan J H, Geng L, Yazlovitskaya E M, et al. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3β in irradiated vascular endothelium [J]. Cancer Res, 2006, 66(4): 2320-2327. Endo H, Nito C, Kamada H, et al. Activation of the Akt/GSK3β signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats [J]. J Cereb Blood Flow Metab, 2006, 26(12): 1479-1489. Dou S, Li Z J, Zheng B Y, et al. ROCK inhibition promotes axon and myelin regeneration via PI3K/Akt/GSK3β in a mouse sciatic nerve injury model [J]. Int J Mol Med, 2025, 57(1): 1-12.
PDF下载
全屏
36
9
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
